This Press Release is Acting as a Correction to the Financial Tables in the Previous Release

Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR)

Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time

Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR)

Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time

Survey Reveals Global Healthcare Buyers Shifting IT Purchases to Regional Providers Amid Regulatory and Geopolitical Concerns

CS DIAGNOSTICS CORP. ANNOUNCES THE APPOINTMENT OF FDA CONSULTANTS

Innovative tissue spacer technology for cancer radiology treatments

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Latest investment follows previously-announced investment in TRNR of $2.9M, reflecting investor's increased enthusiasm for Company's growth and acquisition strategy, including last week's Letter of Intent

Accomplished Technology Executive and Entrepreneur Wensheng Fan Joins DeepRx Inc.

Partnership Focuses on Investigating the Use of CAMPS (Cellular, Acellular and Matrix-like Products) in Hard-to-Heal Pressure Ulcers

The lawsuit consumes valuable taxpayer-funded resources.

What is Hantavirus?  How Can I Prevent It? JP McHale Pest Management Has the Answers

Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories

As the automotive and electronics industries undergo rapid transformation, HAHN Automation Group is setting new benchmarks in technological excellence. With over 30 years of experience, a strong U.S. presence, and a global network, we are uniquely positioned to address industry challenges and drive automation forward.

Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results

Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28

All three doses met the primary endpoint of clinical response at Week 12, with a favorable safety profile

These results in ulcerative colitis build on strong data recently reported for the plaque psoriasis Phase 3 program

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study

Topline results from Phase 3 ICONIC-ADVANCE 1&2studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsO

Results pave the way to initiate the first-ever head-to-head study (ICONIC-ASCEND) seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe PsO

Unveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots

Advanced VELDONA^® development with key Japan patent, Taiwan Tanabe partnership, and IRB approval for Sjögren's syndrome clinical study

Practical partnership for AI Nose, multiple new opportunities

AI Nose to change robotics landscape with first AI smell sensing

Increasing Patient Wellness With Thoughtful Connections

2025 American Medical Informatics Association Summit "Uniting Data-Driven Informatics" Set for March 10-13 in Pittsburgh

Azalea House Hospitality Offers Masters Tickets

23-Year-Old Influencer Receives a Double-Lung Transplant From the FBI

New leadership strengthens AGFA HealthCare's commitment to customer-driven value, innovation, and enhancing the user experience.

Honoring Dr. Churchwell's legacy and impact as a health equity champion for all children!

Target earned more than $15M in revenue in 2024 and TRNR expects to improve target's profitability materially through potential operating synergies

All-stock consideration with long lock-up - expected to close soon, reflecting months of discussions and due diligence - would be TRNR's second transaction in 2025 already

Deal adds further momentum to TRNR growth strategy of making accretive acquisitions of high-potential businesses in the highly fragmented, global health & wellness market

A Major Breakthrough in Ainos' Mission to Digitize Scent

First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more

Por primera vez un hablante nativo de kaqchikel se dirigió a una conferencia mundial de la UNESCO completamente en una lengua ancestral. El educador, autor y guía espiritual maya Baldomero Cuma Chávez hizo historia en París, Francia, en la Conferencia LT4ALL 2025: Language Technologies for All, con una convincente presentación sobre la preservación digital de las lenguas mayas.

Only the best for AGI's monkeys

The National Children's Cancer Society is honored to have Kevin Bouse bring his heart, passion, and leadership to its Board of Directors. With his unwavering dedication, the organization is able to reach even more families, ensuring that no child fights cancer alone.

Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology

The United Kingdom is the world's 3rd largest fitness market

New UK Partner, Cranlea Human Performance, has sold CLMBRs to leading UK health clubs, including David Lloyd Clubs

Cranlea's 50-Year History and Leading In-Market Relationships are expected to significantly strengthen CLMBR's position in the UK

The future of home care is here, and it's virtual.